UNIGE document Scientific Article
previous document  unige:20691  next document
add to browser collection
Title

Continuous Sunitinib treatment in patients with advanced hepatocellular carcinoma: a Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) multicenter phase II trial (SAKK 77/06)

Authors
Koeberle, Dieter
Montemurro, Michael
Samaras, Panagiotis
Simcock, Mathew
Lerch, Stefanie
Kovacs, Katalin
show hidden authors show all authors [1 - 14]
Published in The Oncologist. 2010, vol. 15, no. 3, p. 285-292
Abstract BACKGROUND: Sunitinib (SU) is a multitargeted tyrosine kinase inhibitor with antitumor and antiangiogenic activity. The objective of this trial was to demonstrate antitumor activity of continuous SU treatment in patients with hepatocellular carcinoma (HCC). PATIENTS AND METHODS: Key eligibility criteria included unresectable or metastatic HCC, no prior systemic anticancer treatment, measurable disease, and Child-Pugh class A or mild Child-Pugh class B liver dysfunction. Patients received 37.5 mg SU daily until progression or unacceptable toxicity. The primary endpoint was progression-free survival at 12 weeks (PFS12). RESULTS: Forty-five patients were enrolled. The median age was 63 years; 89% had Child-Pugh class A disease and 47% had distant metastases. PFS12 was rated successful in 15 patients (33%; 95% confidence interval, 20%-47%). Over the whole trial period, one complete response and a 40% rate of stable disease as the best response were achieved. The median PFS duration, disease stabilization duration, time to progression, and overall survival time were 1.5, 2.9, 1.5, and 9.3 months, respectively. Grade 3 and 4 adverse events were infrequent. None of the 33 deaths were considered drug related. CONCLUSION: Continuous SU treatment with 37.5 mg daily is feasible and has moderate activity in patients with advanced HCC and mild to moderately impaired liver dysfunction. Under this trial design (>13 PFS12 successes), the therapy is considered promising. This is the first trial describing the clinical effects of continuous dosing of SU in HCC patients on a schedule that is used in an ongoing, randomized, phase III trial in comparison with the current treatment standard, sorafenib (ClinicalTrials.gov identifier, NCT00699374).
Keywords AdultAgedAged, 80 and overAntineoplastic Agents/ therapeutic useCarcinoma, Hepatocellular/ drug therapy/pathologyDisease-Free SurvivalFemaleHumansIndoles/ therapeutic useLiver Neoplasms/ drug therapy/pathologyMaleMiddle AgedPyrroles/ therapeutic useTreatment Outcome
Identifiers
PMID: 20203173
Full text
Article - document accessible for UNIGE members only Limited access to UNIGE
Other version: http://theoncologist.alphamedpress.org/
Structures
Research group Groupe Roth Arnaud (oncologie) (285)
Citation
(ISO format)
KOEBERLE, Dieter et al. Continuous Sunitinib treatment in patients with advanced hepatocellular carcinoma: a Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) multicenter phase II trial (SAKK 77/06). In: The Oncologist, 2010, vol. 15, n° 3, p. 285-292. https://archive-ouverte.unige.ch/unige:20691

186 hits

0 download

Update

Deposited on : 2012-05-23

Export document
Format :
Citation style :